AnteoTech has lifted its Trading Halt with this annoucement & Presentation
1. AnteoTech secures new funding to support sales launch and accelerate test pipeline (attached)
Highlights
- AnteoTech receives firm commitments to raise $12m through the issue of ~46.2m new fully paid ordinary shares at $0.26 per share
- Funds to be used to scale up the roll-out of the EuGeni reader and COVID-19 ART, and accelerate the development of other assay tests
- Placement was strongly supported by new institutional and sophisticated investors
- Share Purchase Plan to be launched to raise additional $4m from eligible, existing shareholders at $0.26 per share,
2. Investor Presentation
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02367876-2A1294780?access_token=83ff96335c2d45a094df02a206a39ff4
The Cap Raise & SPP price is 26cps. the share closing price was 41.5cps and now (2:45pm) is 42cps.
DISC: I hold